Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

PHASE4TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

June 11, 2015

Study Completion Date

June 11, 2015

Conditions
Moderate to Severe Rheumatoid Arthritis
Interventions
BIOLOGICAL

Etanercept

Administered by subcutaneous injection

DRUG

Methotrexate

Background methotrexate at least 15 mg weekly

Trial Locations (45)

11787

Research Site, Smithtown

16635

Research Site, Duncansville

23320

Research Site, Chesapeake

24016

Research Site, Roanoke

26301

Research Site, Clarksburg

28210

Research Site, Charlotte

30046

Research Site, Lawrenceville

33511

Research Site, Brandon

33609

Research Site, Tampa

33774

Research Site, Largo

34684

Research Site, Palm Harbor

34698

Research Site, Dunedin

35406

Research Site, Tuscaloosa

37343

Research Site, Hixson

42003

Research Site, Paducah

42101

Research Site, Bowling Green

44130

Research Site, Middleburg Heights

49017

Research Site, Battle Creek

68516

Research Site, Lincoln

77034

Research Site, Houston

77901

Research Site, Victoria

78404

Research Site, Corpus Christi

78731

Research Site, Austin

80230

Research Site, Denver

85258

Research Site, Scottsdale

91723

Research Site, Covina

92108

Research Site, San Diego

92395

Research Site, Victorville

92543

Research Site, Hemet

92563

Research Site, Murrieta

98133

Research Site, Seattle

02720

Research Site, Fall River

V8V 3P9

Research Site, Victoria

E2E 4J8

Research Site, Quispamsis

A1A 5E8

Research Site, St. John's

A1C 5B8

Research Site, St. John's

L7R 1E2

Research Site, Burlington

L8N 1Y2

Research Site, Hamilton

L5M 2V8

Research Site, Mississauga

M5G 1X5

Research Site, Toronto

H2L 1S6

Research Site, Montreal

H3T 1Y3

Research Site, Montreal

G1V 3M7

Research Site, Québec

G1W 4R4

Research Site, Québec

00725

Research Site, Caguas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY